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Abstract: Long chain polyunsaturated fatty acids (LC-PUFAs) are important mediators in 
improving and maintaining human health over the total lifespan. One topic we especially 
focus on in this review is omega-3 LC-PUFA docosahexaenoic acid (DHA). Adequate DHA 
levels are essential during neurodevelopment and, in addition, beneficial in cognitive 
processes throughout life. We review the impact of DHA on societal relevant metabolic 
diseases such as cardiovascular diseases, obesity, and diabetes mellitus type 2 (T2DM). All of 
these are risk factors for cognitive decline and dementia in later life. DHA supplementation is 
associated with a reduced incidence of both stroke and atherosclerosis, lower bodyweight 
and decreased T2DM prevalence. These findings are discussed in the light of different stages 
in the human life cycle: childhood, adolescence, adulthood and in later life. From this review, 
it can be concluded that DHA supplementation is able to inhibit pathologies like obesity and 
cardiovascular disease. DHA could be a dietary protector against these metabolic diseases 
during a person’s entire lifespan. However, supplementation of DHA in combination with 
other dietary factors is also effective. The efficacy of DHA depends on its dose as well as on 
the duration of supplementation, sex, and age. 
Keywords: docosahexaenoic acid; humans; metabolic diseases; cardiovascular disease; 
obesity; diabetes mellitus type II  
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1. Introduction 
Since the early 1970s, scientists have studied the role of omega-3 LC-PUFA docosahexaenoic acid 
(DHA) in human health. Currently, it has been shown that DHA may be beneficial in several human 
pathologies like cardiovascular diseases, obesity, and diabetes mellitus type 2 (T2DM); DHA is 
associated with a reduced incidence of stroke, atherosclerosis, lower bodyweight and decreased T2DM 
prevalence [1–7]. Nevertheless, research findings are ambiguous and argue over the supplemented dose 
and duration of the supplementation in relation to sex and age differences. In this review, the impact of long 
chain polyunsaturated fatty acids (LC-PUFAs) on current societally highly relevant metabolic diseases 
in humans will be discussed, and, in particular, the role of DHA in connection with diabetes type II 
(T2DM), obesity, and cardiovascular disease (CVD). The following categories are described in this 
review: childhood, adolescence, adulthood, as well as mature and late adulthood, to indicate the effect of 
DHA on metabolic diseases in critical stages of life.  
We searched the PubMed database for original and review articles in English, published from 1993 
to August 2014. The main search topics concerned DHA, the influence of DHA on disorders such as 
T2DM, obesity and CVD. The search strategy was based on the following search terms: DHA, LCPUFA, 
obesity, T2DM, CVD, childhood, adolescence, adulthood, and the elderly. Moreover, we filtered our 
total list of relevant papers by hand, in order to identify new, potentially relevant papers. We selected the 
studies based on titles and abstracts, a selection of these two components was not sufficient, we evaluated 
the whole publication instead. 
Docosahexaenoic Acid (DHA) 
Humans need to obtain adequate levels of essential fatty acids from dietary sources. These lipids are 
important constituents of phospholipids, which are the building blocks of all membranes. An important 
constituent is the essential fatty acid alpha-linolenic acid (ALA), which can be found, for example, in soy 
beans, flaxseed, linseed and walnut oils [8]. Based on its molecular structure, three double cis-bonds and 
an 18-carbon chain, ALA is classified as a long chain polyunsaturated fatty acid (LC-PUFA) (Figure 1). 
ALA can be converted into two other LC-PUFAs: docosahexaenoic acid (DHA) and eicosapentaenoic 
acid. The first step in this process is to convert ALA into an active metabolic product, i.e., eicosapentaenoic 
acid (EPA) (Figure 1) [9,10]. This is done through a double bond creation at the 6th and 5th position 
(∆6- and ∆5-desaturase), and an elongase at the double bond at the 6th position (∆6-elongase). Subsequently, 
EPA can be metabolized into DHA via ∆5-elongation and ∆4-desaturation (Figure 1) [9,10]. The described 
process is limited, and it only occurs in the liver, the cerebrovascular lumen, and astroglial cells [9,11,12]. 
DHA can be converted into potent novel molecules with anti-inflammatory and organ-protective 
properties [13–17] such as the specialized pro-resolving lipid mediators (SPMs), including D- and E-series 
resolvins, neuroprotectins, and maresins (Figure 1) [15–19] via specialized chemical mediators. 
DHA can also be obtained directly from dietary sources such as deep-sea fish, whereby white fish 
such as cod and haddock contain a lower concentration of DHA than oily fish like Atlantic salmon, blue 
mackerel and sardines [8,20,21]. In cold-water deep sea fish, DHA is accumulated through consumption 
of marine microalgae which are able to synthesize DHA [22]. Cold-water deep-sea fish that live in oceanic 
seas with high water pressure and low temperatures need adequate levels of long chain poly-unsaturated 
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fatty acids like DHA to maintain functional membrane fluidity. Neuronal membranes containing high 
concentrations of saturated fatty acids would become rigid and lose functionality in these cold oceanic 
seas [23].  
Figure 1. Classification of long chain polyunsaturated fatty acids (LC-PUFAs). PUFAs are 
subdivided into two subclasses: omega-6 and omega-3 PUFAs. Within the omega-6 PUFAs 
class precursor fatty acid, (i.e.,) linoleic acid (LA), is converted into arachidonicacid (AA) 
via ∆6-desaturase, ∆6-elongase and ∆5-desaturase. Subsequently, AA can be metabolized 
into docosapentaenoic acid (DPA) via ∆5-elongase. In the omega-3 fatty acid class, the precursor 
fatty acid, i.e., α-linoleic acid (ALA), is converted into eicosapentaenoic acid (EPA) via  
∆6-desaturase, ∆6-elongase and ∆5-desaturase, which can subsequently be converted into 
docosahexaenoic acid (DHA) via ∆5-elongase and ∆4-desaturase. DHA is the precursor of 
several bioactive products, because it can be converted via enzymatic and non-enzymatic 
oxidation. DHA can be metabolized into e.g., resolvins E1 & E2 and D1–D5, maresin-1 and 
neuroprotectin D1 by means of enzymatic oxidation. These eicosanoids can enter the nucleus 
where they downregulate gene expression, promote inflammation or enter the bloodstream. 
This is where they reduce platelet aggregation and accumulation of fatty acids in the arteries. 
In non-enzymatic oxidation, DHA can be oxidized by radical oxygen species into lipid peroxides 
such as neuroprostanes, isoprostanes, aldehydes and 4-hydroxyhexenal. These peroxides can 
activate transcription factors such as peroxisome proliferator-activated receptors (PPARs) 
and nuclear factor-like 2 (Nrf2), which upregulate gene expression in the nucleus. (∆6/∆5/∆4: 
at the double bond at the 6th/5th/4th position). 
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DHA is an essential component in phospholipids because it maintains membrane fluidity. Membrane 
fluidity can be defined as the optimum transition point between gel and liquid crystal where the neuronal 
lipid bilayer can exist. This condition is of physiological importance for signal transmission. It can be 
strongly influenced by fatty acid composition and should therefore be maintained optimal [24]. Dietary 
intake of specific fatty acids can modify the lipid composition of neurons up to a certain degree [24]. 
Prolonged intake of DHA, for example, will modestly increase brain DHA content and decrease brain 
omega-6 PUFAs content simultaneously, particularly docosapentaenoic acid (DPA) [25]. High 
concentrations of DHA within the lipid bilayer provide neuronal membranes with the flexibility/fluidity 
that is required in order to function properly during axonal and synaptic growth, and improve functioning 
of ion-channels and receptors through better transmission [14,24,26–28]. This is contrary to the fact that 
complete long term dietary deprivation of omega-3 PUFAs depletes the brain of DHA, but will specifically 
increase the brain DPA content of the omega-6 PUFAs family [24]. Thus, the concentration of unsaturated 
fatty acids will be more or less maintained, but the functionality of the membranes can differ drastically 
because of changes in omega-3 and omega-6 ratios. In addition, membrane fluidity will change, possibly 
causing impairment of proper membrane function and signal transmission [24]. 
It has been demonstrated that in mammals, DHA, in free form, rapidly crosses the blood brain barrier 
(BBB), similar to freely diffusible lipophilic drugs [29]. The first transport mechanisms of omega-3 
PUFAs into the cell is described as a rapid diffusion flip-flop across cell membranes [30]. Others suggest 
a protein mediated uptake via fatty acid transport proteins (FATPs), fatty acid binding proteins (FABPs), 
fatty acid translocases (FATs), long chain fatty acyl-CoA synthetases (ACSL) or long chain fatty acyl-CoA 
binding proteins (ACBPs) [31–38]. Flip-Flop diffusion and protein-mediated transmembrane transfer seem 
to co-exist as two separate ways of fatty acid transport into the cell, in which the nature of the membrane, 
type and functional state of the cell, availability and type of fatty acids and differences in hormonal 
environment could be important [39,40].  
2. Metabolic Diseases 
There is an emerging epidemic of obesity in people among all ages in Western societies, and it is  
now burgeoning in non-Western societies. Each year, obesity or obesity-related health conditions lead 
to the death of 2.8 million adults around the world [41]. Even though it has an undefined aetiology, it is 
generally caused by an imbalance of energy intake versus energy output. This results in excessive 
adipose tissue accumulation that may eventually have an adverse effect on human health. The epidemic 
of overweight and obesity has caused a dramatic increase in the number of individuals who are suffering 
from T2DM and premature cardiovascular disease (pCVD) [42]. In the U.S., for example, two-thirds 
(167 million) of adults are diagnosed as being overweight or obese, and another 26 million have T2DM [43]. 
It has been estimated that approximately 80% of all new T2DM cases are due to obesity [44]. Currently, 
T2DM is the most common metabolic disorder, and it has reached epidemic proportions in many 
countries [45]. Insulin resistance and inflammation have played a central role in the pathogenesis of T2DM 
and both have developed long before the onset of the disease [45]. The two to fourfold increase in 
cardiovascular morbidity as well as mortality in diabetic individuals is a major concern [45]. T2DM increases 
the risk of both heart disease and stroke as 50% of people with diabetes die from CVD [46]. Insulin 
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signaling plays a critical role in normal vascular function via endothelial cell nitric oxide production, 
modulation of calcium handling and sensitivity in vascular smooth muscle cells [43].  
Patients with T2DM and/or obesity have a significantly increased risk of heart attack and stroke when 
compared to people who have a normal insulin sensitivity and a normal weight [43]. Thus we can conclude 
that metabolic diseases like CVD, T2DM and obesity, are highly intercorrelated and reinforce each other. 
Studies have shown that DNA, as a dietary component, has beneficial effects on these three metabolic 
diseases [2,3,6,47–50]. DHA supplementation seems to affect symptoms of metabolic diseases by reducing 
plasma triglyceride levels, increasing glucose and insulin sensitivity, as well as reducing atherosclerosis. 
DHA could affect these characteristics through mediating processes such as reducing adipocyte 
differentiation, decreasing adipocyte apoptosis, improving lipolysis as well as insulin metabolism, 
decreasing production of proinflammatory cytokines, improving endothelial function and activating 
large-conductance calcium and voltage-activated potassium (BK) channels [51–55].  
2.1. Processes Mediated by DHA 
2.1.1. Inflammation 
It has been shown that DHA is capable of reducing several inflammatory mechanisms which can  
be of importance in the pathology of CVD, T2DM and obesity. For instance, in Pickup et al. [56] it was 
hypothesized that the innate immune system is involved in the pathogenesis of T2DM. Tumor necrosis 
factor alpha (TNF-α), as well as interleukin-1 & 6 (IL-1 & IL-6) are known to play a major role in the 
pathophysiology of insulin resistance in T2DM [57]. Moreover, endothelial dysfunction in cardiovascular 
disease involves many inflammatory processes, and, for instance cytokine overproduction is associated 
with endothelial dysfunction and atherosclerosis [51,52]. For example, TNF-α can accelerate experimental 
atherosclerosis processes in vivo in human and rat veins, mainly through induction of adhesion molecule 
expression in endothelial and vascular smooth muscle cells, resulting in altered endothelium-dependent 
vasodilation and promotion of endothelial cell apoptosis [51,52,58,59]. In obesity, low state chronic 
adipose inflammation is an early characteristic and DHA is capable of decreasing this low state chronic 
adipose inflammation [60]. For example, DHA is able to downregulate tumor necrosis factor-α (TNF-α), 
interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) secretion in human adipose tissue 
and adipocytes cultures [61]. Resolvin D1, an anti-inflammatory SPM converted from DHA (Figure 1), 
increases both the number of macrophages containing ingested particles and the number of phagocytosed 
particles in adipose tissue, and also reduces macrophage reactive oxygen species production [62]. In 
conclusion, these findings illustrate novel mechanisms through which resolvin D1 and its precursor DHA 
may confer anti-inflammatory actions [62].  
2.1.2. Insulin Metabolism 
DHA may be able to partly restore insulin resistance, which is associated with an increased risk of 
developing T2DM [63–67]. In an obesity mouse model (ob/ob), dietary intake of omega-3 PUFAs induced 
an increase in adiponectin, a regulator to maintain the energy balance [53]. Bioactive SPMs, resolvins E1 
and NPD1 (Figure 1), mimicked the insulin-sensitizing effects and induced adiponectin expression to a 
similar extent to that of rosiglitazone, a member of the thiazolidinedione family of antidiabetic drugs [53]. 
Mar. Drugs 2014, 12 6195 
 
 
Together, these findings reveal effects of DHA and its bioactive SPMs in preventing obesity-induced insulin 
resistance via mimicking insulin sensitizing and expression of adiponectin.  
2.1.3. Adipocytes 
It has been demonstrated that DHA is involved in reducing symptoms of obesity via inhibiting 
adipocyte differentiation [60,67–73]. The direct effect of DHA on cell growth, differentiation, apoptosis, 
and lipolysis in adipocyte cell cultures was investigated [74]. Proliferation of preconfluent pre-adipocytes 
was not affected by the DHA treatment, but by DHA inhibited differentiation-associated mitotic clonal 
expansion [74]. DHA decreased mean droplet size and percent lipid area in adipocytes in a dose-dependent 
manner and, moreover, postconfluent pre-adipocytes demonstrated apoptosis after DHA treatment [74]. 
Additionally, DHA increased basal lipolysis in fully differentiated adipocytes [74]. These findings indicate 
that DHA may exert its obesity lowering effect by inhibiting differentiation of pre-adipocytes, inducing 
apoptosis in postconfluent pre-adipocytes and promoting lipolysis in adipocyte cell culture [74].  
2.1.4. Cardiovascular Health 
It is well-known that omega-3 LC-PUFAs are able to improve vascular function; these effects were 
first described in Greenland Inuits [75]. Research revealed that omega-3 LC-PUFAs prevent myocardial 
infarction and arrhythmia, decrease systolic and diastolic blood pressure and improve vascular  
function [76–80]. Individuals receiving omega-3 LC-PUFA supplementation, for example, had a decreased 
risk ratio in cardiac events like atrial fibrillation, nonfatal myocardial infarction and stroke [76,78–80]. 
Omega-3 LC-PUFAs have been shown to decrease systolic and diastolic blood pressure and development 
of hypertension [77]. In Thies et al. it was reported that consumption of omega-3 LC-PUFAs contributed 
to the stability of atherosclerotic plaques [81]. In Baumann et al. it was shown that the transcription of 
pro-inflammatory molecules was decreased after taking an omega-3 LC-PUFA supplementation for four 
weeks, followed by an improved vascular reactivity and endothelial function [80,82]. In addition,  
omega-3 LC-PUFAs can improve vascular function via endothelium relaxation [83]. It has been shown 
in in vivo studies that endothelium relaxation was higher in rodents and humans treated with omega-3 
PUFAs [58,59,84]. Moreover, it was reported that DHA rapidly and reversibly activates BK-channels [54]. 
In vascular smooth muscle cells, BK-channels provide a critical vasodilatory influence [54]. BK  
channels are thus possible receptors for DHA and by activating these BK channels, blood pressure may 
be lowered [54].  
2.2. DHA & Metabolic Diseases in Childhood 
Prevalence of childhood overweight and obesity has rapidly increased worldwide, and at the same 
time prevalence of T2DM and CVD has increased, even from a very early age [85]. To illustrate this,  
two-thirds of severely obese children aged 12 or younger develop cardiovascular risk factors [85]. In a 
study of Salvatore et al. [86] performed in the USA, 80% of the obese children had a low high-density 
lipoprotein (HDL) cholesterol level which is a risk factor for atherosclerosis [86]. In the Netherlands in 
2009, 13.3% of the boys and 14.9% of the girls were diagnosed with obesity, and 62% of these obese 
children aged 12 or younger developed hypertension [85]. It was shown that a daily supplementation of 
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omega-3 LC PUFA improves vascular function and lowers the degree of inflammation in obese 
adolescents [47]. Interestingly, daily consumption of 300 mg DHA and 42 mg for a period of three weeks 
led to improvement of the anthropometric and lipid parameters in obese children aged 8–12 years [87]. 
Damsgaard et al. found that DHA plasma levels were positively associated with mean arterial pressure 
in boys. Moreover, girls had a higher body fat percentage, increased diastolic blood pressure and heart 
rate, elevated plasma triglyceride and insulin levels, and increased insulin resistance and glycosylated 
hemoglobin in comparison to boys [88]. Burrows et al. [2] and Decsi et al. [3] revealed that lower levels 
of DHA in plasma phospholipids are associated with insulin resistance, T2DM and obesity in children. 
Moreover, Juarez-Lopez et al. found that a LC-PUFA supplementation for a 12-week period reduced 
BMI and decreased the concentrations of glucose, insulin, triglyceride-levels in the plasma of obese 
children [89]. These findings indicate that an adequate level of DHA may be of importance in the 
prevention of these chronic diseases in later life [2,3]. 
Thus, DHA levels in childhood are associated with reduced plasma insulin, glucose and triglyceride 
levels. These are all characteristics of obesity and T2DM, and, therefore, an adequate LC-PUFA level may 
be of great importance in preventing metabolic diseases later in life. Nonetheless, other LC-PUFAs such 
as EPA may contribute towards this prevention as well as factors such as sex and age differences. 
2.3. DHA & Metabolic Diseases in Adolescence 
Obesity in children continues to evolve into adolescence, and thereby it contributes to the risk of 
health problems like insulin resistance, hypertension and even brain abnormalities [85,90,91]. Omega-3 
PUFAs supplementation , including DHA, has beneficially affected female obesity in adolescence as it 
improved glucose tolerance by 39% and restored insulin concentration by 34% during an intravenous 
glucose tolerance test (IVGTT) [92]. In contrast, with regard to male obesity in adolescence, neither of these 
two parameters were influenced by omega-3 PUFAs supplementation [92]. In conclusion, omega-3 
PUFAs supplementation seems to be beneficial in restoring insulin concentration and glucose tolerance 
in adolescent girls [92], which additionally indicates that sex differences can be differentially affected 
by omega-3 LC-PUFA supplementation (Table 1). 
Risé et al. examined blood fatty acid levels particularly LC-PUFA levels in Italian neonates, children, 
adults and the elderly, and they found that LC-PUFA levels indicated significant differences due to age 
and sex [93]. In addition, Damsgaard et al. and Dangardt et al. found differences in DHA plasma levels, 
glucose tolerance, diastolic blood pressure, heart rate, plasma triglyceride and insulin levels, homeostasis 
model assesment-insulin resistance and glycosylated levels between sexes [88,92]. These findings 
emphasize that the differing need for LC-PUFAs like DHA depends on age and sex. Future research should 
therefore focus on these diverse needs of sex and age.  
2.4. DHA and Metabolic Diseases in Adults 
Prevalence of obesity, T2DM and CVD increases enormously in adults in the western world [41,94]. 
In the US in 2012, 167 million adults were obese or overweight, 36 million adults had CVD and 24 million 
adults suffered from T2DM [95]. Labonte et al. [96] suggested a minor impact of DHA on T2DM incidence 
in adults [97]. However, Stirban et al. [98] revealed that individuals with T2DM who received an omega-3 
LCPUFA supplementation for a period of six weeks showed a postprandial decrease in macrovascular 
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function (Table 1) [98]. These observations suggest that omega-3 LC PUFAs protect the macrovascular 
function in individuals with T2DM [98].Secondly, Virtanen and colleagues reported that men with 
higher serum level of LC-PUFAs had a 33% lower multivariate-adjusted risk for T2DM [99]. (Table 1). 
Purified DHA supplementation reduced both collagen aggregation and collagen-stimulated thromboxane 
release in hypertensive diabetic individuals, making DHA an effective anti-thrombotic agent [100]. In 
hypertensive T2DM patients it was shown that a DHA and EPA supplementation during eight weeks 
can diminish platelet superoxide production, which suggests a therapeutic role for DHA as well as EPA 
in reducing vascular-derived oxidative stress associated with T2DM [101]. Supplementation with 
purified DHA reduces serum triglycerides and collagen aggregation, increases high-density lipoprotein 
2 (HDL2) cholesterol, besides improving blood pressure [100,102–105]. In obese adults, higher plasma 
levels of total omega-3 PUFAs are associated with a healthier BMI, waist circumference and hip 
circumference [6]. DHA supplementation decreased plasma triglycerides and VLDL-triglycerides in 
noninsulin-dependent diabetes mellitus (NIDDM) hypertriglyceridemia patients and hypertriglyceridemic 
men [106,107]. Moreover, supplementation with conjugated linoleic acids (CLAs) plus omega-3 LC-PUFAs 
prevents increased abdominal fat mass and raises fat-free mass and adiponectin levels in obese adults, 
without deleteriously affecting insulin sensitivity, whereas in lean adults these parameters were 
unaffected [108]. More specifically, LC-PUFA supplementation decreased the gene expression of most 
analyzed inflammatory genes in subcutaneous adipose tissue, and increased production of anti-inflammatory 
eicosanoids in visceral adipose tissue and subcutaneous adipose tissue [109]. Furthermore, it has been 
shown that treatment with omega-3 PUFAs diminishes adipocyte differentiation, stimulates adipocyte 
apoptosis, improves lipid metabolism and systemic inflammation [5,62,84,98,108–110], through 
previously described processes such as anti-inflammatory, adipocyte apoptosis and differentiation.  
A well-studied effect of LC-PUFAs, EPA and DHA is that intake of these fatty acids protects against 
cardiovascular disease because it decreases blood pressure and atherosclerosis formation [75,111–114]. 
These beneficial effects are due to the capacity to prevent arrhythmias, thus improving vasoactivity, 
decreasing blood pressure and inflammation and decreasing atherosclerosis [75,83,110–120]. The 
advantages of taking omega-3 LC-PUFA supplementation are that arrhythmias is prevented, vasoactivity 
is improved and blood pressure, inflammation and atherosclerosis are decreased [1,75,83,110–121]. 
Nevertheless, it was revealed that in healthy adults DHA supplementation did not improve the endothelial 
function [7].  
Thus, omega-3 LC-PUFA supplementation may mainly affect obesity in adults by reducing adiposity 
and inflammation, and LC-PUFAs may improve vascular function by reducing the blood pressure, 
heartrate and coronary calcification. Nonetheless, research findings are ambiguous and therefore more 
research is needed, while taking dosing and duration of LC-PUFA or DHA supplementation into account.  
 
Mar. Drugs 2014, 12 6198 
 
 
Table 1. DHA and metabolic diseases through lifetime. 
Lifetime Author Year N Age (Years) DHA  Outcome 
Childhood       
 Desci [3] 2002 80 ♂ & ♀ 12 Plasma phospholipids ARA & DHA 
Values of arachidonic acid and docosahexaenoic acid were 
significantly lower in diabetic children than in controls. 
 Burrows [2] 2011 48 ♂ & ♀ 
Non-obese: 9.0 ± 0.9 
Obese: 8.9 ± 1.2 
Erythrocyte fatty acid; the Omega-3 
index (O3I) composition 
Obese children had altered erythrocyte fatty acid composition 
unrelated to reported dietary intake. A greater proportion of 
obese children had an omega-3 index of <4.0 (high risk) 
compared with non-obese children. 
 
Vasickova 
[87] 
2011 120 ♂ & ♀ (obese) 10.0 ± 1.9 
300 mg/day DHA + 42 mg/d EPA 
for 3 weeks 
Daily consumption of 300mg DHA and 42 mg EPA for three 
weeks leads to an improvement of the anthropometric and lipid 
parameters in obese children [87].  
 
Juarez Lopez 
[89] 
2013 
201 ♂ & ♀ (obese 
and insulin 
resistant) 
11.6 ± 0.7 
12 weeks LC-PUFA 
supplementation, 360 mg EPA & 
240 mg DHA daily 
LC-PUFA supplementation for 12 weeks decreased the 
concentrations of glucose, insulin, triglyceride-levels and BMI. 
 
Damsgaardt 
[88] 
2013 73 ♂ & ♀ 10.29 ± 0.58 Plasma DHA &EPA concentrations 
DHA was positively associated with mean arterial pressure  
in boys. 
Adolescence       
 
Dangardt 
[92] 
2012 25 ♂ & ♀ 
15.6 ± 0.9 ♀  
15.7 ± 1.0 ♂ 
1,2 g/d LC-PUFAs (DHA & EPA) 
for 3 months 
Three months of supplementation of omega-3 LCPUFA 
improved glucose and insulin homeostasis in obese girls 
without influencing body weight. 
Adulthood       
 
Rivellese 
[107] 
1997 
16 ♂ & ♀ (NIDDM 
patients with 
hypertriglyeridemia) 
56.0 ± 3.0 
First two months: 0.96gr EPA and 
1.59 g DHA per day Last four 
months: 0.64 gr EPA and 1.06 gr 
DHA per day 
DHA and EPA significantly reduced plasma triglycerides and 
VLDL- triglycerides without significant changes in blood 
glucose control. 
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Table 1. Cont. 
 Mori [105] 1999 
56 ♂(overweight & 
hyperlipidemic) 
49.1 ± 1.2  
4 g/day DHA, EPA or olive oil 
(placebo) for 6 weeks 
Purified DHA but not EPA reduced ambulatory BP and HR in 
mildly hyperlipidemic men. 
 Mori [104] 2000 
59 ♂ (overweight & 
hyperlipidemic) 
50.6 ± 1.4  
4 g/day DHA, EPA or olive oil 
(placebo) for 6 weeks 
DHA enhances vasodilator mechanisms and attenuates 
constrictor responses in the forearm microcirculation. 
 
Woodman 
[102] 
2003 
♂ & ♀ 
(Hypertensive and 
diabetic) 
40–75 
4 g/day DHA, EPA or olive oil 
(placebo) for 6 weeks 
DHA increased low density lipoprotein particle size 
 Kelley [106] 2007 34 ♂  55.0 ± 2.0 7.5 g DHA-oil for 90 days 
DHA supplementation for 45 d significantly decreased 
concentrations of fasting triacylglycerol, large VLDL, and 
intermediate-density lipoproteins and the mean diameter of 
VLDL particles. 
 
Sneddon 
[108] 
2008 69 ♂ 32.4 ± 2.3 
3 g/day CLA + 3 g/day omega-3 
LC-PUFAs 
Supplementation with conjugated linoleic acids (CLAs) plus 
omega-3 LC-PUFAs prevents increased abdominal fat mass 
and raises fat-free mass and adiponectin levels in obese adults 
 Micallef [6] 2009 124 ♂ & ♀ 43.79 ± 2.22 Plasma levels of DHA & EPA 
BMI, waist circumference and hip circumference were 
inversely correlated with n-3 PUFA, EPA and DHA (p < 0.05 
for all) in the obese group. Obese individuals had significantly 
lower plasma concentrations of total n-3 PUFA, compared 
with healthy-weight individuals. 
 Stirban [98] 2010 34 ♂ & ♀ (T2DM) 56.8 ± 8.3 2 g/d EPA & DHA for 6 weeks 
Six weeks of supplementation with LC-PUFAs reduced the 
postprandial decrease in macrovascular function relative to 
placebo. LC-PUFAs supplementation improved postprandial 
microvascular function. 
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Table 1. Cont. 
 Itariu [109] 2012 55 ♂ & ♀ (obese) 39.0 ± 2.0 3,36 g/d EPA & DHA for 8 weeks 
n-3 PUFAs, which was well tolerated, decreased the gene 
expression of most analyzed inflammatory genes in 
subcutaneous adipose tissue (p <0.05) and increased 
production of anti-inflammatory eicosanoids in visceral 
adipose tissue and subcutaneous adipose tissue (p <0.05). 
 Labonte [96] 2013 
12 ♂ (obese 
+T2DM) 
54.1 ± 7.2 3 g/d EPA & DHA for 8 weeks 
In obese patients with T2DM, EPA&DHA supplementation 
did not affect the gene expression of pro-inflammatory 
cytokines in duodenal cells.  
 Singhal [7] 2013 328 ♂ & ♀ 28.1 ± 4.8 1.6 g/day DHA 
DHA supplementation did not improve endothelial function in 
healthy adolescents. Only triglyceride and very low-density 
lipoprotein concentrations were significant lower in  
DHA-supplemented individuals compared with controls. 
 
McDonald 
[101] 
2013 
22 ♂ & ♀ 
Hypertensive and 
T2DM 
58.6 ± 8.8 
Daily supplementation of 1.8 g EPA 
and 1.5 g DHA for 8 weeks 
LC-PUFAs diminish platelet superoxide production in T2DM 
hypertensive patients in vivo. 
 Virtanen [99] 2013 2122 ♂ 53.1 ± 5.1 Serum levels DHA, EPA, DPA 
Men with higher serum level of EPA+DHA+DPA had a 33% 
lower multivariate-adjusted risk for T2DM. (Trend: p = 0.01) 
Mature and late adulthood      
 
Woodman 
[100] 
2003 
51 (39-♂ & 12-♀) 
(Hypertensive and 
diabetic) 
61.2 ± 1.2 
4 g/day DHA, EPA or olive oil 
(placebo) for 6 weeks 
DHA supplementation significantly reduced collagen 
aggregation and collagen-stimulated thromboxane release. 
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Table 1. Cont. 
 
Lemaitre 
[122] 
2003 
54: Ischemic heart 
disease  
125:non-fatal 
myocardial 
infarction  
179: matched 
controls ♂ & ♀ 
79.1 ± 7.5 DHA & EPA plasma phospholipids 
Higher combined dietary intake of DHA and EPA, and 
possibly α-linolenic acid, may lower the risk of fatal ischemic 
heart disease in older adults. 
 
Tsitouras 
[123] 
2008 12 ♂ & ♀ 66.1 ± 4.5 
Supplemented with 4 g/day EPA 
and DHA 
Insulin sensitivity increased significantly after 8 weeks on the 
EPA- and DHA-diet, and serum C-reactive protein was 
significantly reduced. 
 
Heine-Böring 
[5] 
2010 
1570 (686-♂ &  
884-♀) 
64.0 ± 5.42 - ♂  
64.0 ± 5.6 -♀ 
Food intake questionnaire; Dutch 
food composition table (DHA & 
EPA levels) 
Subjects with a fish intake >19 g/d had a significantly lower 
prevalence of mild/moderate calcification. EPA plus DHA 
intake showed no significant associations. 
 Djousse [48] 2011 3088 ♂ & ♀ 75.0 
Plasma phospholipids DHA  
and EPA 
DHA is not associated with a higher incidence of T2DM, and 
individuals with higher EPA and DHA plasma concentrations 
had lower risk on T2DM. 
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid; CLA: conjugated linoleic acids; CHF: congestive heart failure; T2DM: diabetes 
mellitus type 2; NIDDM: non-insulin-dependent diabetes mellitus; VLDL: very-low-density-lipoprotein; N: number of participants; Age is represented in years and  
in Mean ± SD. Mean age >4 and ≤12 Year → childhood; Mean age >12 and ≤21 → adolescence; Mean age >21 and ≤60 → adulthood; Mean age >60 → middle and  
late adulthood. 
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2.5. DHA and Metabolic Diseases in Mature and Late Adulthood 
Prevalence of metabolic diseases increases with age. Manzato et al., for example, described that in 
Northern Italy metabolic diseases are present in 25.6% of elder men and in 48.1% of elder women [124]. 
Moreover, their prevalence was mainly due to high blood pressure (93% in both sexes) and to abdominal 
obesity (in 73% of women) [124]. The prevalence of cardiovascular diseases was significantly higher among 
subjects diagnosed with metabolic diseases [124]. Moreover, Czernichow et al. suggested that BMI was 
inversely correlated with resting capillary density, which suggests a lower baseline tissue perfusion; an 
association with higher vasomotor tone in overweight in the elderly [125].  
The incidence of T2DM in older individuals was not associated with DHA plasma phospholipid  
levels [48] (Table 1). However, Tsitouras and colleagues reported that following a DHA and EPA diet 
for a period of eight weeks significantly increased insulin sensitivity in the elderly [123]. Omega-3  
LC-PUFA consumption can provide protection against cardiovascular disease by improving 
vasoactivity, and decreasing blood pressure and inflammation. It was shown that a higher plasma 
concentration of DHA, EPA and DPA in older adults is associated with lower systolic blood pressure, pulse 
pressure and congestive heart failure (CHF), but not with diastolic blood pressure [50,126]. In addition, a 
higher combined DHA and EPA plasma phospholipids level was associated with a lower risk of fatal 
ischemic heart disease [122]. DHA supplementation significantly reduced collagen aggregation and 
collagen-stimulated thromboxane release, which indicates that highly purified DHA may be a more 
effective anti-thrombotic agent than EPA [100]. Furthermore, it was reported that healthy elderly people 
with a higher fish intake had a significantly lower prevalence of moderate coronary calcification [5]. On 
the other hand, intake of EPA plus DHA showed no significant associations [5]. These findings indicate 
that not only DHA is associated with a reduction of cardiovascular risk factors. It is a combination of 
these omega-3 fatty acids, DHA, EPA and DPA that seems to provide these beneficial effects on  
vascular health.  
3. Conclusions 
Omega-3 LC-PUFA supplementation in children and adolescents showed beneficial effects on reducing 
pathological characteristics in obesity, T2DM and CVD by decreasing adipocyte differentiation, 
increasing adipocyte apoptosis, promoting lipolysis, improving endothelial function, lowering blood 
pressure, decreasing inflammation, improving glucose tolerance and decreasing BMI [2,3,92,127,128]. 
Moreover, omega-3 LC-PUFAs reduce obesity symptoms and improve vascular health in adults and the 
elderly. Nevertheless, the impact of DHA can be ambiguous, and is affected by differences in age, 
gender, and health. Other limitations are found in differences in DHA dosing; concentrations differ 
between human studies, which makes comparison of research findings difficult.  
DHA can spontaneously be converted via non-enzymatic oxidation by reactive oxygen species into 
neuroprostanes, isoprostanes, isofuranes, alkenes, alkanes and aldehydes (Figure 1). These lipid peroxides, 
previously thought to have a harmful effect on cells, can activate gene expression changes via peroxisome 
proliferator-activated receptors (PPARs) and nuclear factor-like 2 (Nfr2). In addition, these molecules 
can also have a direct influence on ion-channel conductance, activity of proteins/enzymes via carbonyl 
modification, inhibition of adhesion and atherosclerosis progression [129–134]. These recent findings 
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emphasize a need for multi-nutrient diets, for example LC-PUFAs combined with vitamins and anti-oxidants. 
These dietary factors could inhibit or stimulate the molecular processes as described and, therefore, reinforce 
each other’s beneficial effects in an optimal combination. So, future research should focus on determining 
this optimal DHA-dose, depending on age and gender, and, secondly, combinations of several dietary factors 
like LC-PUFAs and anti-oxidants should be examined. In addition, a multi-nutrient diet could establish 
a multifactorial approach on inflammation and vasodilation, for instance. 
DHA has been suggested to play a role in the prevention and better management of obesity, T2DM 
and cardiovascular disease. Recently, several studies have revealed that obesity, T2DM and CVD are 
correlated with the risk of dementia and AD in later life [135–139]. Therefore, DHA may protect against 
cognitive decline via two pathways; firstly, by reducing the development of diseases like obesity, T2DM 
and CVD. Secondly, by protecting against cognitive decline via maintaining membrane fluidity, 
increasing synaptogenesis, stimulating neurogenesis, decreasing neuroinflammation and improving 
cerebral blood flow [54,62,75,83,84,98,110–120]. Metabolic diseases like obesity, CVD and T2DM 
significantly and independently increase the risk of neurodegeneration and are therefore risk factors in 
the development of dementia and AD [140–142].  
Further understanding is needed to define optimal doses per age and sex, in order to target these different 
metabolic diseases and to assess the relative efficiency of omega-3 LC-PUFAs, specifically DHA. Taken 
altogether, DHA could be one of the dietary protectors throughout a lifetime. 
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